Drug Trial Radar · NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Last checked: Nov 19, 2026Latest source record: Aug 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Feb 23, 2021
Primary completion
Oct 2022
Study completion Mar 2024
Sponsor
- Lead sponsor
- Kartos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Conditions
- Diffuse Large B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Non Hodgkin Lymphoma
Interventions
KRT-232Drug
KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth
acalabrutinibDrug
acalabrutinib is a BTK inhibitor anticancer drug taken by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Objective Phase 1b:To determine the KRT-232 maximum tolerated dose/ maximum administered dose (MTD/MAD) and recommended Phase 2 Dose (RP2D) in combination with acalabrutinib in subjects with R/R DLBCL or R/R CLLTime frame: 56 Days
- Primary Objective Phase 2: Cohort 1: To determine the complete response (CR)Time frame: 1 Year
- Primary Objective Phase 2: Cohort 2: To determine the rate of CR/complete remission with incomplete hematologic recovery (CRi) rate in R/R CLLTime frame: 1 Year
Locations
45 sites in 11 countries. Site status is shown where the registry gives one.
Goshen Center for Cancer Care
Goshen, Indiana · Recruiting
University of Cincinnati
Cincinnati, Ohio · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Royal Adelaide Hospital
Adelaide, Australia · Recruiting
Eastern Health - Box Hill Hospital
Box Hill, Australia · Recruiting
Barwon Health
Geelong, Australia · Recruiting
Royal Perth Hospital
Perth, Australia · Recruiting
Antwerp University Hospital (UZA)
Edegem, Belgium · Recruiting
Jessa Ziekenhuis
Hasselt, Belgium · Recruiting
University Hospital (UZ) Leuven
Leuven, Belgium · Recruiting
Fakultni Nemocnice Hradec Kralove
Nový Hradec Králové, Czechia · Recruiting
Fakultni nemocnice Ostrava
Ostrava, Czechia · Recruiting
Vseobecna fakultni nemocnice v Praze
Prague, Czechia · Recruiting
CHU de Nantes - Hôtel-Dieu
Nantes, France · Recruiting
Centre Henri Becquerel
Rouen, France · Recruiting
CHRU de Tours - Hôpital Bretonneau
Tours, France · Recruiting
Centro Riferimento Oncologico - Aviano
Aviano, Italy · Recruiting
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Italy · Recruiting
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy · Recruiting
IRCCS Ospedale San Raffaele
Milan, Italy · Recruiting
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy · Recruiting
Centro Ricerche Cliniche di Verona s.r.l.
Verona, Italy · Recruiting
Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii
Gdansk, Poland · Recruiting
Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii
Gdansk, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach - Klinika Transplantacji Szpiku i Onkohematologii
Gliwice, Poland · Recruiting
Pratia MCM Krakow
Krakow, Poland · Recruiting
Szpital Uniwersytecki Krakow - Oddzial Kliniczny Hematologii
Krakow, Poland · Recruiting
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu
Wroclaw, Poland · Recruiting
Hospital de Braga
Braga, Portugal · Recruiting
Centro Hospitalar Universitario de Lisboa Norte - Hospital de Santa Maria
Lisbon, Portugal · Recruiting
Champalimaud Cancer Center
Lisbon, Portugal · Recruiting
Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
Porto, Portugal · Recruiting
Centro Hospitalar de Vila Nova de Gaia/Espinho EPE
Vila Nova de Gaia, Portugal · Recruiting
National Cancer Center
Goyang, South Korea · Recruiting
Gachon University Gil Medical Center
Incheon, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Seoul St. Mary's Hospital
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.